Controlled-delivery formulations of cannabidiol to optimize the treatment of triple negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma characterized by the absence of estrogen receptors, progesterone receptors, and HER2 receptors. These tumors are fast-growing and have a higher recurrence rate and worse prognosis compared to other breast cancer subtypes....
| Autor: | |
|---|---|
| Formato: | tesis doctoral |
| Fecha de publicación: | 2026 |
| País: | España |
| Recursos: | Universidad Complutense de Madrid (UCM) |
| Repositorio: | Docta Complutense |
| Idioma: | inglés |
| OAI Identifier: | oai:docta.ucm.es:20.500.14352/133812 |
| Acesso em linha: | https://hdl.handle.net/20.500.14352/133812 |
| Access Level: | acceso abierto |
| Palavra-chave: | 616-006.04-085(043.2) Cancer Oncología 3207.13 Oncología |
| Resumo: | Triple-negative breast cancer (TNBC) is an aggressive form of breast carcinoma characterized by the absence of estrogen receptors, progesterone receptors, and HER2 receptors. These tumors are fast-growing and have a higher recurrence rate and worse prognosis compared to other breast cancer subtypes. It is noteworthy that around 45% of TNBC patients develop metastasis. Chemotherapy is the primary therapeutic strategy for this disease. However, it shows significant limitations due to their high toxicity. In this regard, the use of adjuvant compounds with low toxicity that enhance the efficacy of antineoplastics, allow the reduction of the doses of these drugs, and consequently their side effects, is of great interest... |
|---|